Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Jeserschek, R; Clar, H; Aigner, C; Rehak, P; Primus, B; Windhager, R.
Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study.
J Bone Joint Surg Br. 2003; 85(2):174-177 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar


Autor/innen der Med Uni Graz:
Aigner Christian
Clar Heimo
Jeserschek Reinhard
Rehak Peter
Windhager Reinhard

Dimensions Citations:

Plum Analytics:
We have investigated in a prospective,randomised placebo-controlled study the effect of high-dose aprotinin on blood loss in patients admitted for major surgery (revision arthroplasty of the hip or knee, or for resection of a soft-tissue sarcoma). The mean intraoperative blood loss was reduced from 1957 ml in the control group to 736 ml in the aprotinin group (p = 0.002). The mean requirement for intraoperative homologous blood transfusion in the aprotinin group was 1.4 units (95% CI 0.2 to 2.7) and 3.1 units (95% CI 1.7 to 4.6) in the control group (p = 0.033). The mean length of hospital stay was reduced from 27.8 days in the control group to 17.6 days in the aprotinin group which was not statistically significant. The intraoperative use of aprotinin in major orthopaedic operations significantly reduced blood loss and the required amount of packed cells. It may result in in the length of hospital stay and costs.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged, 80 and over -
Aprotinin - therapeutic use
Blood Loss, Surgical - prevention and control
Blood Transfusion - prevention and control
Double-Blind Method - prevention and control
Female - prevention and control
Hemostasis, Surgical - methods
Hemostatics - therapeutic use
Humans - therapeutic use
Intraoperative Care - methods
Length of Stay - methods
Male - methods
Middle Aged - methods
Orthopedic Procedures - methods
Prospective Studies - methods
Serine Proteinase Inhibitors - therapeutic use

© Meduni Graz Impressum